MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction-Reference-Cited by-同舟云学术

MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction

Published:2017-03 Issue:3 Volume:28 Page:642-650
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Janku F.,Huang H.J.,Fujii T.,Shelton D.N.,Madwani K.,Fu S.,Tsimberidou A.M.,Piha-Paul S.A.,Wheler J.J.,Zinner R.G.,Naing A.,Hong D.S.,Karp D.D.,Cabrilo G.,Kopetz E.S.,Subbiah V.,Luthra R.,Kee B.K.,Eng C.,Morris V.K.,Karlin-Neumann G.A.,Meric-Bernstam F.

Funder

National Institutes of Health

National Center for Advancing Translational Sciences

Sidney Kimmel Foundation for Cancer Research; Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy; National Center for Advancing Translational Sciences

National Institutes of Health through MD Anderson’s Cancer Center

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/3/642/11203429/mdw670.pdf

Reference32 articles.

1. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials;Said;Oncotarget,2014

2. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer;Hutchins;J Clin Oncol,2011

3. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome;Ihle;J Natl Cancer Inst,2012

4. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors;Garrido-Laguna;PLoS One,2012